SCHEMBL4873486

SCHEMBL4873486

CCOc1ccc2nccc(CC(=O)c3cccc(C)n3)c2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 4/20 0.47
HPGD P15428 3/20 0.47
KDM4E B2RXH2 3/20 0.47
HSD17B10 Q99714 2/20 0.47
CYP1A2 P05177 1/20 0.47
TSHR P16473 1/20 0.47
MTNR1A P48039 5/20 0.42
MTNR1B P49286 3/20 0.42
MAPT P10636 9/20 0.41
LMNA P02545 6/20 0.41
RAB9A P51151 4/20 0.41
NPC1 O15118 3/20 0.41
TP53 P04637 3/20 0.41
PKM P14618 2/20 0.41
KMT2A Q03164 2/20 0.40
NPSR1 Q6W5P4 2/20 0.40
GBA1 P04062 1/20 0.40
OPRK1 P41145 1/20 0.40
POLB P06746 2/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5238328 0.92 THRB (0.44) SMN1; SMN2ALDH1A1HPGDKDM4EHSD17B10
SCHEMBL23851296 0.90 MTNR1A (0.52) ALDH1A1HPGDKDM4EHSD17B10CYP1A2
SCHEMBL31461239 0.90 MTNR1A (0.52) ALDH1A1HPGDKDM4EHSD17B10CYP1A2
SCHEMBL5233120 0.86 TRPV1 (0.44) MTNR1AMTNR1BTP53TGFBR1
SCHEMBL3747756 0.83 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1KDM4ETSHRLMNA
SCHEMBL24322279 0.83 CDK8 (0.39) SMN1; SMN2ALDH1A1KDM4EHSD17B10RAB9A
SCHEMBL31461243 0.83 ALDH1A1 (0.39) SMN1; SMN2ALDH1A1KDM4ETSHRLMNA
SCHEMBL29959459 0.82 CYP1A2 (0.49) SMN1; SMN2ALDH1A1CYP1A2RAB9ATGFBR1
SCHEMBL5235225 0.82 CYP1A2 (0.49) SMN1; SMN2ALDH1A1CYP1A2RAB9ATGFBR1
SCHEMBL5235795 0.82 KDR (0.45) ALDH1A1CYP1A2MTNR1AMTNR1BLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7365066-B2 Pyrazolopyridine derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-04-29 US disclosed
US-7365066-B2 Pyrazolopyridine derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-04-29 US disclosed
US-7365066-B2 Pyrazolopyridine derivatives as pharmaceutical agents ELI LILLY AND COMPANY (US) 2008-04-29 US disclosed
EP-1543001-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2007-08-15 EP disclosed
EP-1543001-B1 PYRAZOLOPYRIDINE DERIVATIVES AS TGF BETA SIGNAL TRANSDUCTION INHIBITORS FOR THE TREATMENT OF CANCER LILLY CO ELI (US) 2007-08-15 EP disclosed
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents BEIGHT DOUGLAS W 2005-10-06 US disclosed
EP-1543001-A1 NOVEL PYRAZOLOPYRIDINE DERIVATIVES AS PHARMACEUTICAL AGENTS ELI LILLY AND COMPANY (US) 2005-06-22 EP disclosed
WO-2004026871-A1 NOVEL PYRAZOLOPYRIDINE DERIVATVES AS PHARMACEUTICAL AGENTS ELI LILLY AND COMPANY (US) 2004-04-01 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050222197-A1 Novel pyrazolopyridine derivatives as pharmaceutical agents TGFB2, TGFB1, TGFBR1 SMN1; SMN2 4070/4885ALDH1A1 1975/4885HPGD 374/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.